Skip to main content
Oruka Therapeutics, Inc. logo

Oruka Therapeutics, Inc. — Investor Relations & Filings

Ticker · ORKA ISIN · US6876041087 US Manufacturing
Open in API
Filings indexed 997 across all filing types
Latest filing 2024-09-06 Director's Dealing
Country US United States of America
Listing US ORKA

About Oruka Therapeutics, Inc.

https://orukatx.com/

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel biologics for chronic skin diseases and other inflammatory conditions. The company applies advanced antibody engineering to validated modes of action to create potentially best-in-class monoclonal antibodies. Its lead program, ORKA-001, targets the IL-23 cytokine for the treatment of moderate-to-severe plaque psoriasis. Oruka's mission is to redefine the standard of care by developing treatments that achieve high rates of complete disease clearance with a significantly reduced dosing frequency, potentially requiring only one or two doses per year.

Recent filings

Filing Released Lang Actions
Director's Dealing 2024
Director's Dealing
2024-09-06 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The text describes a business combination (merger) between ARCA biopharma, Inc. and Oruka Therapeutics, Inc., including details of the merger agreement, stock conversions, support and lock-up agreements, and a financing transaction related to the merger. The document is not a full annual or quarterly report, nor is it a proxy statement or earnings release. It is a regulatory filing reporting a significant corporate event (merger and related financing). Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories but are regulatory announcements.
2024-09-05 English
PRIMARY DOCUMENT
Director's Dealing
2024-08-30 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by ARCA biopharma, Inc. dated August 26, 2024. It announces an update regarding a special cash dividend amount in connection with a proposed merger with Oruka Therapeutics, Inc. It also discusses a reverse stock split and the expected trading symbol change post-merger. The document includes forward-looking statements about the merger and related risks. There are no financial statements or detailed financial data included, only an announcement of events and a press release attached as an exhibit. The document is not a full annual or quarterly report, nor is it a proxy statement or earnings release. It is a regulatory filing reporting a material event (merger update and dividend announcement). Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-08-27 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by ARCA biopharma, Inc. It announces an update regarding a special cash dividend amount in connection with a proposed merger with Oruka Therapeutics, Inc. The document includes details about the reverse stock split, dividend payment date, and forward-looking statements related to the merger. It also references a press release as an exhibit. The content focuses on merger-related events and dividend announcements rather than full financial statements or earnings results. The document is not a full annual or quarterly report, audit report, or earnings release. It is primarily an announcement of a corporate event (merger and dividend update) filed as a regulatory disclosure. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2024-08-27 English
CURRENT REPORT
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by ARCA biopharma, Inc. It details the submission of matters to a vote of security holders at a special meeting related to a merger agreement, including voting results on multiple proposals. The document also includes information about the expected consummation of the merger, a reverse stock split, and related corporate actions. The content focuses on the official results of shareholder votes at a special meeting and related corporate governance actions. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting (AGM or EGM). The document is not a proxy statement, not a full annual or quarterly report, nor a merger filing itself, but a report of voting results. Therefore, the correct classification is DVA with high confidence.
2024-08-23 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.